EICHOR
● Recruiting
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer · Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
About this study
The aim of the study to evaluate the safety and efficacy of Sacituzumab Tirumotecan in combination with osimertinib or as monotherapy for neoadjuvant treatment in patients with resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer.
This description comes directly from the study's public registry record.
Talk to the study team
Yina Diao · 028-67252634 · diaoyina@kelun.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.